Lumos Diagnostics
Helps to develop and manufacture custom rapid Point-of-Care diagnostic solutions.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | AUD5.0m | Post IPO Debt |
| Total Funding | 000k | ||
| USD | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (9 %) | 6 % | 16 % | 24 % | 48 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (161 %) | (41 %) | (44 %) | (21 %) | 6 % | 6 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (393 %) | (85 %) | (77 %) | (48 %) | (16 %) | (10 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 11 % | 4 % | 1 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Lumos Diagnostics specializes in developing, manufacturing, and commercializing custom rapid point of care (POC) diagnostic solutions. The company operates in the healthcare diagnostics market, serving clients ranging from healthcare providers to pharmaceutical companies. Lumos Diagnostics leverages its ISO 13485 certified manufacturing facility and co-located technical R&D team to minimize the time and risk associated with transferring products into production. This integrated approach ensures ongoing support and high-quality output.
The business model of Lumos Diagnostics revolves around providing tailored diagnostic solutions that meet specific client needs. This includes the development of proprietary Lumos-branded POC diagnostic tests and assays, which can be configured as standalone manual read products or integrated with Lumos readers or third-party hardware for fully automated solutions. Additionally, Lumos has developed a digital technology platform that allows clients to utilize cloud-based services to create a comprehensive product ecosystem, enhancing the capability of diagnostic readers.
Lumos Diagnostics generates revenue through direct commercial sales of its proprietary diagnostic tests, custom development projects, and ongoing support services. By offering a combination of product sales and bespoke development services, the company ensures a diversified income stream.
Keywords: Point of care, diagnostic solutions, ISO 13485, custom development, rapid tests, healthcare diagnostics, digital platform, cloud-based services, automated solutions, proprietary assays.